Table 4.

Pharmaceutical formulations of GT ingredients investigated in different studies on eye diseases.

Pharmaceutical formulation	Advantages of formulation	Reference
EGCG loaded in anionic liposome with Poloxamer-407 & magnesium	Enhance antioxidant activity and efficacy in the treatment of oxidative stress in ocular disease	[161]
PEG/catechin nanocomplex	Increase tear production, stabilize tear film, and better anti-inflammatory effect in dry eye disease	[162]
Catechin binding to PEG	Enhance solubility of catechin and show significant anti-inflammatory effect in dry eye disease	[163]
Gelatin–epigallocatechin gallate/hyaluronic acid nanoparticles	Better anti-inflammation effect in Dry-eye syndrome (DES)	[148]
GEH-RGD nanoparticle	Angiogenesis inhibitor in cornea neovascularization	(145)
EGCG loaded in CTAB & DDAB (cationic lipid)	Show Better Bioavailability, stability, biodegradability, and prolonged release of EGCG and safety for treatment of ocular disease	[164]
Epigallocatechin Gallate in Gelatin-g-Poly (N-Isopropylacrylamide)	Leading to extended-release formulation, and increased pharmacological efficacy in dry eye syndrome	[165]

PEG: Poly Ethylene Glycol.

GEH: Gelatin-EGCG with Hyaluronic acid.

RGD: Arginine-Glycine-Aspartic.

CTAB: Cetyltrimethylammonium bromide.

DDAB: dimethyldioctadecylammoniumbromide